ABBVAbbVie Inc.| Quarter | Revenue | Gross Profit | Op. Income |
|---|---|---|---|
| Q1 23 | $12.2B | $8.2B | $2.8B |
| Q2 23 | $13.9B | $9.6B | $4.5B |
| Q3 23 | $13.9B | $7.4B | $2.3B |
| Q4 23 | $14.3B | $8.6B | $3.2B |
| Q1 24 | $12.3B | $8.2B | $2.8B |
| Q2 24 | $14.5B | $10.3B | $4.0B |
| Q3 24 | $14.5B | $10.2B | $3.8B |
| Q4 24 | $15.1B | $10.7B | -$1.5B |
| Q1 25 | $13.3B | $9.3B | $3.7B |
| Q2 25 | $15.4B | $11.1B | $4.9B |
| Q3 25 | $15.8B | $10.5B | $1.9B |
| Q4 25 | $16.6B | $14.0B | $5.8B |
| Quarter | P/S | P/E |
|---|---|---|
| Q1 23 | 7.1x | 53.1x |
| Q2 23 | 7.2x | 46.4x |
| Q3 23 | 7.3x | 61.9x |
| Q4 23 | 7.4x | 82.8x |
| Q1 24 | 7.4x | 67.2x |
| Q2 24 | 7.3x | 75.5x |
| Q3 24 | 7.3x | 78.7x |
| Q4 24 | 7.2x | 94.2x |
| Q1 25 | 7.0x | 96.0x |
| Q2 25 | 6.9x | 107.1x |
| Q3 25 | 6.8x | 168.7x |
| Q4 25 | 6.6x | 95.3x |
| Quarter | Operating CF | Free CF |
|---|---|---|
| Q1 23 | $4.2B | $4.0B |
| Q2 23 | $6.3B | $6.1B |
| Q3 23 | $7.6B | $7.4B |
| Q4 23 | $4.8B | $4.5B |
| Q1 24 | $4.0B | $3.8B |
| Q2 24 | $2.3B | $2.0B |
| Q3 24 | $5.4B | $5.2B |
| Q4 24 | $7.0B | $6.8B |
| Q1 25 | $1.6B | $1.4B |
| Q2 25 | $5.2B | $4.9B |
| Q3 25 | $7.0B | $7.5B |
| Q4 25 | $5.2B | $4.9B |
| Quarter | CapEx |
|---|---|
| Q1 23 | $175M |
| Q2 23 | $178M |
| Q3 23 | $219M |
| Q4 23 | $205M |
| Q1 24 | $193M |
| Q2 24 | $241M |
| Q3 24 | $249M |
| Q4 24 | $291M |
| Q1 25 | $235M |
| Q2 25 | $269M |
| Q3 25 | $504M |
| Q4 25 | $329M |
| Quarter | Revenue Growth | OpEx Growth |
|---|---|---|
| Q1 23 | -9.7% | +7.2% |
| Q2 23 | -4.9% | -17.2% |
| Q3 23 | -6.0% | +14.1% |
| Q4 23 | -5.4% | +15.5% |
| Q1 24 | +0.7% | +0.6% |
| Q2 24 | +4.3% | +11.9% |
| Q3 24 | +3.8% | -8.7% |
| Q4 24 | +5.6% | +49.4% |
| Q1 25 | +8.4% | +1.0% |
| Q2 25 | +6.6% | +0.6% |
| Q3 25 | +9.1% | +30.5% |
| Q4 25 | +10.0% | -34.9% |
| Quarter | SBC ($) | % of Revenue |
|---|---|---|
| Q1 23 | $313M | 2.6% |
| Q2 23 | $179M | 1.3% |
| Q3 23 | $130M | 0.9% |
| Q4 23 | $125M | 0.9% |
| Q1 24 | $348M | 2.8% |
| Q2 24 | $218M | 1.5% |
| Q3 24 | $181M | 1.3% |
| Q4 24 | $674M | 4.5% |
| Q1 25 | $410M | 3.1% |
| Q2 25 | $179M | 1.2% |
| Q3 25 | $209M | 1.3% |
| Q4 25 | $157M | 0.9% |
| Quarter | R&D | SG&A |
|---|---|---|
| Q1 23 | $2.3B | $3.0B |
| Q2 23 | $1.7B | $3.3B |
| Q3 23 | $1.7B | $3.4B |
| Q4 23 | $2.2B | $3.2B |
| Q1 24 | $1.9B | $3.3B |
| Q2 24 | $1.9B | $3.4B |
| Q3 24 | $2.1B | $4.2B |
| Q4 24 | $6.8B | $3.9B |
| Q1 25 | $2.1B | $3.3B |
| Q2 25 | $2.1B | $3.3B |
| Q3 25 | $2.3B | $3.6B |
| Q4 25 | $2.6B | $3.9B |
| Quarter | Alphagan/Combigan | Botox Cosmetic | Botox Therapeutic | Duodopa | H U M I R A | Imbruvica | Juvederm Collection | Linzess/Constella | Lumigan/Ganfort | Mavyret | Other Aesthetics | Other Eye Care | Other Neuroscience | Other Products | Ozurdex | Rinvoq | Restasis | Skyrizi | Ubrelvy | Venclexta | Vraylar | Qulipta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 23 | $71M | $659M | $719M | $118M | $3.5B | $878M | $355M | $259M | $130M | $364M | $286M | $200M | $79M | $691M | $115M | $686M | $92M | $1.4B | $152M | $538M | $561M | — |
| Q2 23 | $65M | $685M | $748M | $117M | $4.0B | $907M | $368M | $278M | $119M | $387M | $331M | $215M | $70M | $741M | $119M | $918M | $99M | $1.9B | $196M | $571M | $658M | $96M |
| Q3 23 | $70M | $620M | $748M | $118M | $3.5B | $908M | $321M | $288M | $91M | $370M | $298M | $207M | $61M | $782M | $120M | $1.1B | $117M | $2.1B | $233M | $590M | $751M | $132M |
| Q4 23 | $66M | $718M | $776M | $115M | $3.3B | $903M | $334M | $283M | $92M | $309M | $319M | $181M | $66M | $821M | $118M | $1.3B | $128M | $2.4B | $234M | $589M | $789M | $180M |
| Q1 24 | $59M | $633M | $748M | $115M | $2.3B | $838M | $297M | $266M | $91M | $349M | $319M | $200M | $74M | $744M | $131M | $1.1B | $57M | $2.0B | $203M | $614M | $694M | $131M |
| Q2 24 | $49M | $729M | $814M | $113M | $2.8B | $833M | $343M | $221M | $103M | $369M | $318M | $225M | $80M | $810M | $124M | $1.4B | $32M | $2.7B | $231M | $637M | $774M | $150M |
| Q3 24 | $62M | $671M | $848M | $111M | $2.2B | $828M | $258M | $234M | $116M | $302M | $310M | $207M | $84M | $726M | $119M | $1.6B | $21M | $3.2B | $269M | $677M | $875M | $176M |
| Q4 24 | $78M | $687M | $873M | $108M | $1.7B | $848M | $279M | $233M | $119M | $291M | $332M | $215M | $100M | $752M | $120M | $1.8B | $114M | $3.8B | $303M | $655M | $924M | $201M |
| Q1 25 | $60M | $556M | $866M | $96M | $1.1B | $738M | $231M | $148M | $106M | $306M | $315M | $217M | $59M | $747M | $123M | $1.7B | — | $3.4B | $240M | $665M | $765M | $193M |
| Q2 25 | $36M | $692M | $928M | $97M | $1.2B | $754M | $260M | $258M | $103M | $375M | $327M | $250M | $55M | $603M | $125M | $2.0B | — | $4.4B | $338M | $691M | $900M | $267M |
| Q3 25 | $47M | $637M | $985M | $96M | $993M | $706M | $253M | $326M | $97M | $312M | $303M | $248M | $46M | $660M | $117M | $2.2B | — | $4.7B | $354M | $726M | $934M | $288M |
| Quarter | Non-US | United States |
|---|---|---|
| Q1 23 | $3.0B | $9.2B |
| Q2 23 | $3.1B | $10.7B |
| Q3 23 | $3.1B | $10.9B |
| Q4 23 | $3.2B | $11.1B |
| Q1 24 | $3.3B | $9.0B |
| Q2 24 | $3.4B | $11.1B |
| Q3 24 | $3.3B | $11.1B |
| Q4 24 | $3.4B | $11.7B |
| Q1 25 | $10.0B | $3.4B |
| Quarter | Cash | Short-term Investments | Total |
|---|---|---|---|
| Q1 23 | $6.7B | $11M | $6.7B |
| Q2 23 | $8.8B | $7M | $8.8B |
| Q3 23 | $13.3B | $3M | $13.3B |
| Q4 23 | $12.8B | $2M | $12.8B |
| Q1 24 | $18.1B | $2M | $18.1B |
| Q2 24 | $13.1B | $27M | $13.2B |
| Q3 24 | $7.3B | $28M | $7.3B |
| Q4 24 | $5.5B | $31M | $5.6B |
| Q1 25 | $5.2B | $1M | $5.2B |
| Q2 25 | $6.5B | $0 | $6.5B |
| Q3 25 | $5.6B | $42M | $5.7B |
| Q4 25 | $5.2B | $28M | $5.3B |
| Quarter | Shares (Diluted) | QoQ Change |
|---|---|---|
| Q1 23 | 1.78B | -0.1% |
| Q2 23 | 1.77B | -0.3% |
| Q3 23 | 1.77B | +0.0% |
| Q4 23 | 1.77B | +0.1% |
| Q1 24 | 1.77B | +0.1% |
| Q2 24 | 1.77B | -0.1% |
| Q3 24 | 1.77B | +0.1% |
| Q4 24 | 1.77B | +0.1% |
| Q1 25 | 1.77B | -0.1% |
| Q2 25 | 1.77B | +0.0% |
| Q3 25 | 1.77B | +0.0% |
| Q4 25 | 1.77B | +0.1% |
| Year | Revenue/Employee | Employees |
|---|---|---|
| FY 14 | $768K | 26K |
| FY 15 | $816K | 28K |
| FY 16 | $855K | 30K |
| FY 17 | $973K | 29K |
| FY 18 | $1M | 30K |
| FY 19 | $1M | 30K |
| FY 20 | $975K | 47K |
| FY 21 | $1M | 50K |
| FY 22 | $1M | 50K |
| FY 23 | $1M | 50K |
| FY 24 | $1M | 55K |
| FY 25 | $1M | 57K |